ARDENT HEALTH PARTNERS INC (ARDT)
US03980N1072 - Common Stock
Taking everything into account, ARDT scores 3 out of 10 in our fundamental rating. ARDT was compared to 109 industry peers in the Health Care Providers & Services industry. ARDT has a bad profitability rating. Also its financial health evaluation is rather negative. ARDT is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ARDT was profitable.
1.2 Ratios
The Return On Assets of ARDT (1.12%) is comparable to the rest of the industry.
ARDT has a Return On Equity of 5.36%. This is in the better half of the industry: ARDT outperforms 65.74% of its industry peers.
The Return On Invested Capital of ARDT (4.70%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.12% | ||
| ROE | 5.36% | ||
| ROIC | 4.7% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARDT has a Profit Margin of 1.00%. This is in the better half of the industry: ARDT outperforms 60.19% of its industry peers.
ARDT has a Operating Margin (3.99%) which is in line with its industry peers.
ARDT has a better Gross Margin (55.93%) than 79.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.99% | ||
| PM (TTM) | 1% | ||
| GM | 55.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARDT is destroying value.
The number of shares outstanding for ARDT remains at a similar level compared to 1 year ago.
The debt/assets ratio for ARDT has been reduced compared to a year ago.
2.2 Solvency
ARDT has an Altman-Z score of 1.87. This is not the best score and indicates that ARDT is in the grey zone with still only limited risk for bankruptcy at the moment.
ARDT has a Altman-Z score (1.87) which is comparable to the rest of the industry.
ARDT has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
ARDT has a worse Debt to Equity ratio (1.08) than 64.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.87 |
ROIC/WACC0.62
WACC7.58%
2.3 Liquidity
A Current Ratio of 1.91 indicates that ARDT should not have too much problems paying its short term obligations.
The Current ratio of ARDT (1.91) is better than 70.37% of its industry peers.
A Quick Ratio of 1.78 indicates that ARDT should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.78, ARDT is doing good in the industry, outperforming 70.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
The earnings per share for ARDT have decreased strongly by -71.47% in the last year.
Looking at the last year, ARDT shows a small growth in Revenue. The Revenue has grown by 5.45% in the last year.
EPS 1Y (TTM)-71.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)5.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ARDT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 82.20% yearly.
ARDT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.01% yearly.
EPS Next Y225.04%
EPS Next 2Y130.87%
EPS Next 3Y82.2%
EPS Next 5YN/A
Revenue Next Year10.2%
Revenue Next 2Y9.01%
Revenue Next 3Y8.01%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ARDT is valuated quite expensively with a Price/Earnings ratio of 36.32.
ARDT's Price/Earnings is on the same level as the industry average.
ARDT is valuated rather expensively when we compare the Price/Earnings ratio to 27.28, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.77, the valuation of ARDT can be described as very cheap.
98.15% of the companies in the same industry are more expensive than ARDT, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of ARDT to the average of the S&P500 Index (23.53), we can say ARDT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.32 | ||
| Fwd PE | 6.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ARDT indicates a rather cheap valuation: ARDT is cheaper than 88.89% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.12 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARDT's earnings are expected to grow with 82.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y130.87%
EPS Next 3Y82.2%
5. Dividend
5.1 Amount
ARDT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARDENT HEALTH PARTNERS INC
NYSE:ARDT (1/15/2025, 5:05:01 PM)
After market: 13.8 0 (0%)13.8
-0.25 (-1.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners62.64%
Inst Owner Change0.09%
Ins Owners1.76%
Ins Owner Change1.37%
Market Cap1.97B
Analysts81.25
Price Target23.05 (67.03%)
Short Float %1.5%
Short Ratio6.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.13%
Min EPS beat(2)-44.28%
Max EPS beat(2)10.01%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.59%
Min Revenue beat(2)-2.11%
Max Revenue beat(2)-1.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.47%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.32 | ||
| Fwd PE | 6.77 | ||
| P/S | 0.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.96 | ||
| P/tB | 25.6 | ||
| EV/EBITDA | 7.12 |
EPS(TTM)0.38
EY2.75%
EPS(NY)2.04
Fwd EY14.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS37.9
BVpS7.05
TBVpS0.54
PEG (NY)0.16
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.12% | ||
| ROE | 5.36% | ||
| ROCE | 5.52% | ||
| ROIC | 4.7% | ||
| ROICexc | 5.49% | ||
| ROICexgc | 7.59% | ||
| OM | 3.99% | ||
| PM (TTM) | 1% | ||
| GM | 55.93% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.04 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.87 |
F-ScoreN/A
WACC7.58%
ROIC/WACC0.62
Cap/Depr(3y)102.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y225.04%
EPS Next 2Y130.87%
EPS Next 3Y82.2%
EPS Next 5YN/A
Revenue 1Y (TTM)5.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year10.2%
Revenue Next 2Y9.01%
Revenue Next 3Y8.01%
Revenue Next 5YN/A
EBIT growth 1Y7.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.5%
EBIT Next 3Y50.4%
EBIT Next 5YN/A
FCF growth 1Y144.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y677.96%
OCF growth 3YN/A
OCF growth 5YN/A